Close Menu

NEW YORK — Proteomics firm Seer said today that it has closed a $55 million Series D funding round.

The company plans to use the funds to develop and commercialize its Proteograph proteomics platform for research and clinical applications. According to the company the platform allows for proteomics at a scale and speed not possible with existing platforms.

The round was led by life science venture capital fund aMoon with participation from existing and other new investors.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Following discrimination allegations, NICHD's Constantine Stratakis withdraws from a new position at the Research Institute of the McGill University Health Center, Science reports.

US President Donald Trump has threatened to cut World Health Organization funding over its pandemic response, which would affect its ability to do its work and which he might not be able to do.

The US Securities and Exchange Commission has halted the sales of a handful of stocks over claims made about the coronavirus.

In Nature this week: comparative analyses of single-cell RNA sequencing protocols uncover differences between approaches, and more.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.